bioMérieux recall redux
This article was originally published in The Gray Sheet
Executive Summary
Firm's April 20 recall of Vitek GPS-107 gram positive sensibility cards (lot B28E) is deemed Class I by FDA in 1May 6 letter. bioMérieux received a similar agency communication March 19 regarding the January recall of a separate GPS-107 lot. The recalled cards - used with the automated Vitek for antibiotic susceptibility testing - could report results as if they were GPS-105 cards, which contain ampicillin, levofloxacin and amoxicillin. The first recalled lot affected an estimated 95 clinical laboratory customers (2"The Gray Sheet" March 29, 2004, p. 11)...
You may also be interested in...
bioMérieux Initiates Test Card Recall After Customer Complaint
bioMérieux estimates that 94 clinical laboratory customers are affected by the recall of its Vitek GPS-107 gram positive susceptibility card (lot M58X)
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.